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Abstract: Nowadays, the safety of parabens as pharmaceutical preservatives is debated.
Recent studies investigated their interference with the oestrogen receptors, nevertheless
their carcinogenic activity was also proved. That was the reason why the re-evaluation
of the biocompatibility and antimicrobial activity of parabens is required using modern
investigation methods. We aimed to test the cytotoxic, antifungal and antibacterial effect of
parabens on Caco-2 cells, C. albicans, C. parapsilosis, C. glabrata, E. coli, P. aeruginosa and S. aureus.
Two complex systems (glycerol—Polysorbate 20; ethanol—Capryol PGMC™) were formulated to
study—with the MTT-assay and microdilution method, respectively—how other excipients may
modify the biocompatibility and antimicrobial effect of parabens. In the case of cytotoxicity, the
toxicity of these two systems was highly influenced by co-solvents and surfactants. The fungi
and bacteria had significantly different resistance in the formulations and in some cases the
excipients could highly modify the effectiveness of parabens both in an agonistic and in a
counteractive way. These results indicate that with appropriate selection, non-preservative excipients
can contribute to the antimicrobial safety of the products, thus they may decrease the required
preservative concentration.
Keywords: excipient interaction; surfactant; liquid dosage forms; cytotoxicity; preservative;
Caco-2 cells
1. Introduction
Although tablets and capsules are the most popular types of pharmaceutical dosage forms,
different oral liquid formulations (syrups, herbal extracts, suspensions, emulsions, etc.) still have
specific therapeutic indications, mainly in paediatrics. Flavouring is a crucial part of these formulations
because patient compliance is highly dependent on the taste of the product. Usually they contain
high amount of sweet carbohydrates (glycose, fructose, maltitol, xylitol, sorbitol, etc.), which can be
metabolized by different microorganisms, thus the product can be easily contaminated [1]. It must
be noted, that these liquid preparations are opened and closed multiple times during their life-time
and each application increases the possibility of contamination. In order to avoid it, an appropriate
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amount of preservatives must be used, which can kill or inhibit the growth of bacteria, fungi and
other unicellular. The exact mechanism of action of preservatives is unclear in some cases, but as the
cell membrane is the only common subcellular component in these microbes, they mostly distort the
structure of the membrane resulting in several consequences [2]. Their cytotoxicity is mostly based on
these effects as well [3].
One of the most widely used group of pharmaceutical preservatives is the parabens. They are
derivatives of 4-hydroxybenzoic acid in the form of its carboxylic esters. The most commonly used
parabens (Figure 1) are methyl paraben (MP) (E218), ethyl paraben (EP) (E214), propyl paraben (PP)
(E216), butyl paraben (BP), heptyl paraben and their respective sodium salts. The longer the alkyl
chain, the lower the solubility in water is. Hence, some co-solvent such as ethanol is usually required
to increase their solubility and it must also be noted, that the sodium salts are less frequent in different
formulations. Generally, they are considered as synthetic compounds, but in the recent years many
natural sources were found [4–6]. They are preferred in the pharmaceutical and cosmetic industries,
because of their odourless and tasteless characteristics, great chemical stability over a wide range of
pH values and a broad spectrum of antimicrobial activity [7].
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through the skin from cosmetic products [16,17]. Their direct cytotoxic behaviour has been reported 
on corneal epithelial cells [18], on dermal fibroblasts [19] and on liver cells [20]. Paraben exposure is 
not only restricted to the users of cosmetics [21], as they can pass through the placenta [22] and can 
be measured in the milk of lactating mothers [23]. These results suggest a decline in the use of these 
4-hydroxybenzoic acid derivatives in oral and topical formulations during the next few years.  
An oral, liquid pharmaceutical preparation contains many excipients, which is the reason why 
cytotoxicity tests of each chemical by itself is not enough to gain a comprehensive view of the 
biocompatibility profile of the product. There are only few studies on how the biocompatibility of an 
excipient is influenced if other components are present in the test systems. However, in order to get 
authorized by governmental authorities, the whole product cannot be toxic, but positive interactions 
might decrease the appropriate concentration of additives i.e., the quantity of preservatives may also 
be reduced. However, serious cytotoxicity values may be measured, if the excipients can potentiate 
their harmful effects [24]. As the cytotoxic effects of surface-active agents are well-known [25], they 
might have synergetic antimicrobial activity with preservatives. Different co-solvent mixtures can 
have different biocompatibility profiles and might modify the toxicity of preservatives, increasing 
their effect on the cell membranes by creating a better chemical environment at the site of action [24]. 
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have different biocompatibility profiles and might modify the toxicity of preservatives, increasing their
effect on the cell membranes by creating a better chemical environment at the site of action [24].
In this study, our objective was to investigate the cytotoxicity and antimicrobial properties on
Caco-2 cells and on various pathogenic microorganisms of different 4-hydroxybenzoic acid derivatives
alone and in two complex co-solvent systems to explore interferences between the preservatives and
the component of the co-solvent systems. Caco-2 cells are widely applied as an in vitro model of
human gastrointestinal transport and mainly used as a monolayer rather than individual cells, however
several assays are performed prior to reach complete integrity, such as end point or non-invasive
cell viability assays (MTT assay, LDH test, RT-CES, etc.) [26]. In our antimicrobial experiments, our
test solutions were tested on clinically relevant pathogens: S. aureus as a Gram-positive facultative
anaerobe, E. coli and P. aeruginosa as a Gram-negative aerobes and C. albicans as the most common
fungal pathogen and C. parapsilosis and C. glabrata as the top Candida species opportunistic pathogens
different from C. albicans [27].
The formulations of the investigated systems contain a co-solvent and a surface-active agent.
The first formulation (S1) consisted of 30% (v/v) glycerol and 0.002% (v/v) Polysorbate 20.
The surfactant of the second formulation (S2) was 0.5% (v/v) Capryol PGMC™ and the parabens in
the form of their 10 (w/w)% solutions, dissolved in 70% (v/v) ethanol. Tables 1 and 2 summarize
the composition of every solution used in our experiments. The experimental design is presented
in Figure 2.
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Table 1. Composition of test solutions for cytotoxicity tests.
Component S1 S2
Paraben 0.2 w/w%, 0.02 w/w%, 0.002 w/w%, 0.0002 w/w%
Glycerol 30 v/v%, 3 v/v%, 0.3 v/v%, 0.03 v/v% -
Polysorbate 20 0.002 v/v%, 0.0002 v/v%, 0.00002 v/v%,0.000002 v/v% -
Capryol PGMC™ - 0.5 v/v%, 0.05 v/v%, 0.005 v/v%, 0.0005v/v%
Ethanol - 1.4 v/v%, 0.14 v/v%, 0.014 v/v%, 0.0014v/v%
PBS solvent, used for tenfold, hundredfold, thousand-fold dilution
Table 2. Composition of test solutions for antimicrobial tests.
Component S1 S2 Control
Paraben 0.1 w/w%, 0.15 w/w%, 0.25 w/w%
Glycerol 30 v/v% - -
Polysorbate 20 0.002 v/v% - -
Capryol PGMC™ - 0.5 v/v% -
Ethanol - 0.7 v/v%, 1.05 v/v%, 1.75 v/v% 0.7 v/v%, 1.05 v/v%, 1.75 v/v%
RPMI-1640 solvent for antifungal tests
Mueller-Hinton broth solvent for antibacterial tests
Test solutions were prepared in situ, 10 min before the inoculation for antimicrobial investigations.
Caco-2 cells were incubated for 30 min with the test solutions, then these solutions were removed and
the MTT-solution was added for a 3 h long reaction. The converted formazan crystals were dissolved
in appropriate solvents after the unreacted MTT was removed. Absorbance was measured at two
different wavelengths and the cell viability was calculated. After seeding the bacterial and fungal cells
in appropriate concentrations into 96-well microplates, a 24 h long incubation was started. Optical
density was measured at two wavelengths at the end of the incubation period.
2. Results
2.1. Cytotoxicity Tests
2.1.1. Cytotoxicity of Parabens
In order to mimic the dilution of samples in the gastrointestinal tract, the cytotoxicity of parabens
was measured in tenfold, hundredfold and thousand-fold dilutions (Figure 3). The samples were
diluted by PBS. At 0.2 (w/w)% butyl and ethyl paraben had significantly higher cytotoxicity than
methyl and ethyl paraben, which had similar toxicity patterns. There was a linear relationship between
the cytotoxicity and the dilution ratio of different paraben derivatives. The more concentrated samples
decreased the cell viability and resulted in significant cytotoxicity. The higher the ratio of dilution of
parabens, the better the cell viability of the Caco-2 cell line was.
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Figure 3. Cytotoxicity of parabens on Caco-2 cells measured by MTT-assay. Cell viability was expressed
as the percentage of the absorbance of the untreated control cells. Data expressed as mean ± SEM,
n = 12. Cell viability of the samples at 0.2000; 0.0200; 0.0020; 0.0002 (w/w)% concentrations: P:
81 ± 2.4%; 89% ± 1.6%; 99% ± 3.1%; 100% ± 2%; EP: 83% ± 3.3 ; 88% ± 2.6 ; 100 ± 3.1%;
100% ± 2.5%; PP: 53% ± 4.7%; 78% ± 4%; 97% ± 2.7%; 100% ± 2.7%; BP: 41% ± 4.6%; 81% ± 2.4%;
94% ± 2.9%; 99% ± 2.5%.
2.1.2. Cytotoxicity of Solvents
Ethanol and glycerol were tested in different concentrations diluted with phosphate buffered
saline (PBS) for cytotoxicity experiments. As it can be seen on Figures 4 and 5, the cell viability
decreased in a concentration dependent manner in the case of these solvents. The IC50 (the inhibitory
concentration value, where the 50% cell viability was measured by an MTT test) of glycerol was
45 (v/v)%. In our complex systems, the concentrations of glycerol were 30 (v/v)%, 3 (v/v)%, 0.3 (v/v)%,
0.03 (v/v)% which were lower than this inhibitory concentration.
The concentrations of ethanol (1.75 (v/v)%, 1.4 (v/v)%, 0.14 (v/v)%, 0.014 (v/v)%) in complex
systems were applied for cytotoxicity and antimicrobial tests. Based on this cytotoxicity test, the
IC50 value cannot be determined in these concentration ranges. The cell viability slightly decreased
according to the concentration, but the highest concentration (1.75 (v/v)%) decreased the cell viability
significantly (80 ± 1.7%).
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the absorbance of the untreated control cells. Data expressed as mean ± SEM, n = 12. Cell viability
of the samples at the different concentrations: 100% ± 0.2%; 100% ± 1.8%; 100% ± 3.1%; 100% ± 2%;
95% ± 1.7%; 87% ± 0.5%; 81% ± 1.1%; 72% ± 0.9%; 66% ± 1%.
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Figure 5. Cytotoxicity of glycerol measured by MTT-assay. Cell viability expressed as the percentage of
the absorbance of the untreated control cells. Data expressed as mean ± SEM, n = 12. Cell viability
of the samples at the different concentrations: 100% ± 1.1%; 95% ± 2.5%; 90% ± 2.5%; 83% ± 3.4%;
74% ± 3.6%; 60% ± 2.5%; 50% ± 1.7%; 42% ± 2%; 35% ± 0.4%.
2.1.3. Cytotoxicity of Formulated Systems
The cytotoxicity of S1 can be seen in Figure 6. The formulated control was highly toxic, and
the cell viability was less than 50% compared to the untreated control at the original concentration.
MP had the highest survivability from all esters, the second was EP. The results of the two longer
parabens were not significantly different from each other at the tested concentrations. Moreover,
the methyl paraben was not significantly different from the formulated control, but at the original
concentration and at tenfold dilution, along with ethyl paraben, these derivatives were different from
the longer ones. All statistical differences between the test solutions diminished at hundredfold and
thousand-fold dilutions.
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2.6%; 94% ± 2.9%; 91% ± 2.5%. 
. fi t f l t t ( ) c sisti f 30 (v/
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. ; . ; 0.00 ; 0.0002 (w/
l t c tr l: 48% ± .1%; 100% ± 2.7%; 100% ± 4%; 98% ± 1.8%; formulated MP:
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t other parabens caused nearly total cell death. T e tenfold dilution sh wed another ranking: propyl
and ethyl paraben matched the results of the formulated control, while BP had slightly worse cell
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viability and MP was also significantly more toxic than the formulated control. After further dilution,
all esters, except BP caused 100% cell viability.
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Figure 7. Cytotoxicity of the s cond formulated t (S2) con isting of 0.5% (v/v) Capryol PGMC™
and ethanol measured by MTT-assay. Cell viability expressed as the percentage of the absorbance of the
untreated control cells. Data expressed as mean ± SEM, n = 12. Cell viability of the samples at 0.2000;
0.0200; 0.0020; 0.0002 (w/w)% concentrations of different formulations containing parabens: Formulated
control: 63%± 2.8%; 100%± 2.5%; 100%± 2.5%; 98%± 3.4%; formulated MP: 2%± 0.2%; 90%± 1.8%;
97% ± 3.1%; 99% ± 2%; formulated EP: 4% ± 0.7%; 100% ± 2.7%; 100% ± 3.1%; 100% ± 2.5%;
formulated PP: 5% ± 0.6%; 100% ± 3.2%; 100% ± 2.7%; 100% ± 2.7%; formulated BP: 24% ± 1.2%;
81% ± 2.6%; 94% ± 2.9%; 91% ± 2.5%.
2.2. Antimicrobial Tests
2.2.1. Antifungal Tests
In order to test the antimicrobial properties of parabens, three different concentrations were used.
Cell viability was expressed as a percent of the absorbance of the positive control in the case of every
species, respectively. The critical 50% cell viability threshold was presented with a line in each figure.
Above this value a certain compound is considered ineffective in the case of antimicrobial activity,
while below this line it has an inhibitory effect. We also formulated a control solution for every paraben
to control their normal antimicrobial effects, without any additives.
In the case of C. albicans, (Figure 8) there was no significant difference between formulated and
non-formulated parabens, both the control solutions and the S1 and S2 solutions resulted in the
same results. However, S1-PP, S1-BP and S2-EP had higher cell viability values than their controls, the
formulations decreased the effectiveness of the parabens. There was no difference between the longer
and the shorter esters.
The investigation of C. parapsilosis (Figure 9) showed a high cell viability gap between the control
parabens and the formulations. The control solutions totally eradicated the fungal cells, however,
both formulations slightly increased their survivability. The increase of dissolved paraben did not
reduce this gap, but even further weakened the antimicrobial effect of the parabens. At the highest
concentration, the S1-PP no longer had inhibitory effect at all.
C. glabrata was also sensitive to both the control and the formulated solutions (Figure 10), but
the results of S1 were worse than S2 or the control. This lack of effectiveness increased with the
growing concentration.
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Figure 8. Cell viability of C. albicans against the control paraben solutions (MP; EP; PP; BP); the first
system (S1-MP; S1-EP; S1-PP; S1-BP) and the second system (S2-MP; S2-EP; S2-PP; S2-BP). Cell viability
expressed as the percentage of the absorba ce of the untreated control. Data expressed as mean ± SEM,
n = 4. Cell viability of fungal cells at 0.1; 0.15; 0.25 (w/w)% concentrations of different formulations
containing parabens: MP: 11% ± 2.2%; 10% ± 3.2%; 10% ± 2.5%; EP: 10% ± 3.3%; 10% ± 3.4%;
10%± 4.1%; PP: 11%± 2.2%; 9 2.3%; 9%± 3%; BP: 10%± 1.7%; 10%± 2.2%; 9 ± 3%; formulated
control of S1: 13% ± 1.7 ; formulated MP of S1: 12% ± 3.1%; 13 ± 2.7%; 12% ± 1.4%; formulated EP
of S1: 12%± 2.3%; 12%± 1.9%; 16%± 0.9%; formulated PP of S1: 14%± 0.7%; 16%± 0.5%; 27%± 1.3%;
formulated BP of S1: 15% ± 1.6%; 16% .5%; 32% ± 1 ; formulated control of S2: 18% ± 3.3%;
16% ± 2.5%; 16% ± 2%; formulated MP of S2: 17% ± 2.1%; 16% ± 1.7%; 16% ± 1.7%; formulated EP of
S2: 17% ± 1.5%; 16% ± 0.8%; 32% ± 2%; formulated PP of S2: 17% ± 1.8%; 16% ± 2.2%; 16% ± 0.9%;
formulated BP of S2: 18% ± 1.2%; 17% ± 1.7%; 22% ± 0.8%.
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Figure 9. Cell viability of C. parapsilosis against the control paraben solutions (MP; EP; PP; BP); the first
system (S1-MP; S1-EP; S1-PP; S1-BP) and the second system (S2-MP; S2-EP; S2-PP; S2-BP). Cell viability
expressed as the percentage of the sorbance of the untreated control. Data expressed as mean ± SEM,
n = 4. Cell viability of fungal cells at 0.1; 0.15; 0.25 (w/w) concentrations of differe t formulations
containing parabens: MP: 5% ± 4%; 2% ± 1.5%; 0% + 0.5%; EP: 1% ± 0.8%; 1% ± 0.3%; 0% + 0.1%;
PP: 1% ± 0.1%; 0% + 0.4%; 0% + 0.2%; BP: 0% + 0.4%; 0% + 0.3%; 0% + 0.3 ; formulated control of
S1: 22% ± 1.5 ; formulated MP of S1: 24% ± 1.4 ; 27% ± 1.2%; 25% ± 2%; formulated EP of S1:
23% ± 2.3%; 23% ± 1.7%; 29% ± 1.9%; formulated PP of S1: 24% ± 1.3%; 33% ± 1.2%; 57% ± 0.7%;
formulated BP of S1: 23% ± 1.1%; 34% ± 2%; 38% ± 0.9%; formulated control of S2: 36% ± 2.7%;
44% ± 1.5%; 44% ± 1.8%; formulated MP of S2: 28% ± 1.3%; 30% ± 1.6%; 30% ± 1.8%; formulated
EP of S2: 29% ± 2.2%; 28% ± 1.5%; 31% ± 1.8%; formulated PP of S2: 30% ± 2.3%; 28% ± 2.1%;
27% ± 1.9%; formulated BP of S2: 31% ± 1.2%; 31% ± 1.5%; 33% ± 1.9%.
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Figure 10. Cell viability of C. glabrata against the control paraben solutions (MP; EP; PP; BP); the first
system (S1-MP; S1-EP; S1-PP; S1-BP) and the second system (S2-MP; S2-EP; S2-PP; S2-BP). Cell viability
expressed as the percentage of the absorbance of the untreated control. Data expressed as mean ± SEM,
n = 4. Cell viability of fungal cells at 0.1; 0.15; 0.25 (w/w)% concentrations of different formulations
containing parabens: MP: 11% ± 1.1%; 5% ± 0.7%; 5% ± 2%; EP: 5% ± 2.3%; 4% ± 1.2%; 4% ± 0.9%;
PP: 5% ± 3.2%; 4% ± 1%; 5% ± 1.2%; BP: 5% ± 3%; 5% ± 1.1%; 4% ± 1.2%; formulated control of
S1: 6% ± 1.6%; formulated MP of S1: 14% ± 3.4%; 16% ± 2.5%; 15% ± 2.5%; formulated EP of S1:
14% ± 1.1%; 13% ± 1.4%; 19% ± 2%; formulated PP of S1: 14% ± 0.7%; 15% ± 1.4%; 21% ± 1%;
formulated BP of S1: 14% ± 3.4%; 19% ± 3.2%; 24% ± 2.9%; formulated control of S2: 6% ± 2.9%;
6% ± 2.5%; 6% ± 2%; formulated MP of S2: 5% ± 3.4%; 5% ± 1.4%; 5% ± 2%; formulated EP of S2:
5% ± 1.4%; 5% ± 2.8%; 5% ± 1.7%; formulated PP of S2: 5% ± 4.1%; 5% ± 3.2%; 5% ± 1%; formulated
BP of S2: 1% ± 0.9%; 1% ± 0.8%; 1% ± 0.9%.
2.2.2. Antibacterial Tests
S. aureus (Figure 11) was not sensitive to the control solutions, and increasing doses of MP, EP
and PP did not decrease the cell viability. Meanwhile, the ethanolic solution of BP and S1 proved to
be highly effective. S2 containing Capryol PGMC™ apart from ethanol was also effective, with the
exception of the formulated MP, which only passed the 50% limit at 1.5 (w/w)%.
E. coli (Figure 12) had resistance against EP and BP, except for the S1, which was very effective
against it. The addition of a surface-active agent in S2 could increase the antimicrobial properties of BP
and PP as they showed greater inhibitory effect than the normal ethanolic solutions. S1 showed higher
efficacy than the other solutions.
P. aeruginosa (Figure 13) showed the widest spectrum of resistance. The ethanolic EP, PP and BP
could not inhibit its growth at all, like PP and BP in S2. The presence of Capryol PGMC™ was also
advantageous for the EP and BP, their effectiveness was highly increased, but they still could not reach
a 50% inhibitory rate. All derivatives formulated in S1 were totally effective in every concentration,
and methyl paraben was also effective at the highest dose in S2 and the control ethanolic solutions.
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Figure 11. Cell viability of S. aureus against the c trol paraben solutions (M ; E ; PP; BP); the first
system (S1-MP; S1-EP; S1-PP; S1-BP) and the second system (S2-MP; S2-EP; S2-PP; S2-BP). Cell viability
expressed as the percentage of the absorbance of the untreated control. Data expressed as mean ± SEM,
n = 4. Cell viability of bacterial cells at 0.1; 0.15; 0.25 (w/w)% concentrations of different formulations
containing parabens: MP: 80 2.2%; 66% ± 1.9%; 59% ± 1.5%; EP: 70% ± 2.4%; 70% ± 1.3%;
62% ± 1.6%; PP: 83% ± 2.3%; 66% ± 2.5%; 63% ± 1.4%; BP: 2% ± 1.1%; 1% ± 0.9%; 1% ± 0.4%;
formulated control of S1: 1% ± 0.3%; formulated MP of S1: 2% ± 1.4%; 1% ± 0.5%; 1% ± 0.8%;
formulated EP of S1: 1% ± 0.2%; 1% ± 0.4%; 4% ± 2.8 ; formulated PP of S1: 2% ± 1.6%; 4% ± 1.3%;
6% ± 2.4%; formulated BP of S1: 4% ± 2.1%; 5% ± 6 ; 3% ± 1.5%; formulated control of S2:
37% ± 1.6%; 4% ± 2.7%; 4% ± 1.1%; formulated MP of S2: 61% ± 1.2%; 20% ± 2.6%; 1% ± 0.5%;
formulated EP of S2: 28%± 2.4%; 2%± 1.3%; 1%± 0.9%; formulated PP of S2: 22%± 1.7%; 4%± 2.1%;
0% ± 0% +0.3%; formulated BP of S2: 3% ± 2.5%; 3% ± 1.8%; 3% ± 2.9%.Molecules 2018, 23, x 10 of 19 
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containing parabens: MP: 20% ± 1.7%; 10% ± 2%; 0% + 0.1%; EP: 16% ± 1.2%; 8% ± 1.6 ; 7 1.2 ;
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Figure 13. Cell viability of P. aeruginosa against the control paraben solutions (MP; EP; PP; BP); the first
system (S1-MP; S1-EP; S1-PP; S1-BP) and the second system (S2-MP; S2-EP; S2-PP; S2-BP). Cell viability
expressed as the percentage of the absorbance of the untreated control. Data expressed as mean ± SEM,
n = 4. Cell viability of fungal cells at 0.1; 0.15; 0.25 (w/w)% concentrations of different formulations
containing parabens: MP: 100% ± 2.2%; 72% ± 2.0%; 7% ± 1.2%; EP: 100% ± 2.1%; 100% ± 2.3%;
100% ± 1.7%; PP: 100% ± 1.7%; 100% ± 1.2%; 100% ± 1.8%; BP: 100% ± 1.3%; 100% ± 1.4%; 98% ± 2%;
formulated control of S1: 0% + 0.4%; formulated MP of S1: 0% + 0.2%; 0% + 0.3%; 0% + 0.1%; formulated
EP of S1: 0% + 0.2%; 0% + 0.2%; 0% + 0.3%; formulated PP of S1: 1% + 0.5%; 1% + 0.3%; 1.8% + 0.4%;
formulated BP of S1: 1% + 0.1%; 8% ± 2.1%; 4% ± 1.7%; formulated control of S2: 100% ± 2.6%;
99% ± 1.4%; 99% ± 1.7%; formulated MP of S2: 96% ± 2.5%; 62% ± 1.5%; 4% ± 1.3%; formulated
EP of S2: 100% ± 2%; 92% ± 1.7%; 72% ± 1.3%; formulated PP of S2: 100% ± 2.1%; 100% ± 1.6%;
100% ± 1.8%; Formulated BP of S2: 100% ± 2%; 96% ± 1.4%; 72% ± 1.9%.
3. Discussion
The microbial stability of any oral pharmaceutical product until its expiry date is essential
regardless if the product was contaminated during its application. However, the use of preservatives
is a cheap way to protect any product, there are authorized drugs on the market with ineffective
microbial protection [28]. In our study, we formulated two different co-solvent systems:
S1 which contained 30% (v/v) glycerol and 0.002% (v/v) Polysorbate 20 (HLB value: 16.7) and S2
which contained 0.5% (v/v) Capryol PGMC™ (HLB value: 5) and parabens in the form of their 70%
(v/v) ethanolic solutions [25].
The basis of selection was to use one co-solvent, different surfactants with high and moderate
HLB values and preservatives (parabens) in our investigations, because these excipients are officially
widely applied in liquid, oral pharmaceutical formulations. In order to comply with EMEA guidelines,
these authorized excipients were used in safe concentrations [29]. The cytotoxicity of ethanol and
glycerin as co-solvents were also tested on Caco-2 cell line and their cytocompatible concentrations
were determined. The safe 0.5 (v/v)% ethanol concentration was controlled in OTC products for
children [30]. We applied ethanol as co-solvent in 1.75 (v/v)%, 1.4 (v/v)%, 0.14 (v/v)%, 0.014 (v/v)%
concentration range and these concentrations proved to be cytocompatible on Caco-2 cells. Ethanol
can increase the solubility of several drugs, such as COX-2 inhibitors even at low concentration and it
showed cytotoxic properties at 10% (v/v) on Caco-2 cells [31,32].
The effective glycerol concentration for enhancing the solubility of different active pharmaceutical
ingredients (APIs) was proved from 20% (v/v) [33]. The concentration of glycerol of our complex
systems was used from 30 (v/v)%, 3 (v/v)%, 0.3 (v/v)%, to 0.03 (v/v)% which were lower than the
inhibitory concentration.
The selection of Polysorbate 20 and Capryol PGMC based on our previous experiments [25].
It was found that the safe concentration range of Polysorbate 20 was 0.002 (v/v)%, 0.0002 (v/v)%,
Molecules 2018, 23, 1827 12 of 19
0.00002 (v/v)% and 0.000002 (v/v)%. The HLB value of Polysorbate 20 is high and effective solubilizing
properties can be presented. Surfactant with lower HLB value was Capryol PGMC and cytocompatible
concentration range (0.5 (v/v)%, 0.05 (v/v)%, 0.005 (v/v)%, 0.0005 (v/v)%) was confirmed in our study.
Based on our experimental design, we tested two complex formulations containing different
parabens to evaluate their cytotoxic and antimicrobial interference and to investigate how these
materials influence the safety and efficacy of parabens on human cells, bacteria and fungi—E. coli,
P. aeruginosa, S. aureus, C. albicans, C. parapsilosis, C. glabrata. The antimicrobial stability can depend
on the formulation and the different excipients used in the product. Ribes et al. have found that
the antimicrobial effect of cinnamon leaf essential oil can be heavily enhanced by a nanoemulsion of
emulsifying agents [34]. Han et al. also investigated the effects of preservatives and they found that
there are multiple preservatives which influence the stability of Diprivan® injection (an intravenous
anaesthetic emulsion) in an undesirable way [35].
As it was found, S1 and S2 complex systems had significant concentration dependent cytotoxic
effect on Caco-2 cells. In the in vitro Caco-2 cell line investigations, our systems were diluted with
phosphate buffered saline (PBS). We prepared our solutions 10 minutes before the starting point of
the incubations of Caco-2 cells to prevent any accelerated hydrolysis caused by the other excipients
as the transesterification of parabens by Caco-2 cells after long incubation times was reported [36],
the incubation time was minimized in our MTT-test in order to avoid any significant conversion.
Our experiment was supported by the results of Tomankova et al., because they showed that parabens
were chemically stable, and they only converted by spontaneous hydrolysis in aqueous solutions after
months of storage [37].
It was found that in our test systems the relative toxicity of parabens was different in these two
formulated systems, and the ranking of toxicity was not general. The parabens alone, presented the
ranking of BP > PP > EP > MP as butyl paraben was the most toxic. In most scientific studies, such
as the publication of Dagher et al., it was reported that the cytotoxicity increased with the length
of alkyl chains as well [38]. They investigated that MP was the least toxic on MCF7 breast cancer
cells, while the cytotoxicity of more lipophilic parabens (BP and benzyl paraben) eventually increased.
While the S1 had identical results, in S2, the other excipients could modify the ranking, BP at the
highest concentration was the safest paraben.
In S1, in the presence of glycerol and Polysorbate 20, MP was the least toxic compound, while
the other parabens with longer alkyl chains had similar curves and reached nearly total cell death at
0.2 (w/w)%. At tenfold dilution, the cell viability value of MP was significantly higher than the other
parabens, but at that concentration, EP became distinguishable from the more lipophilic derivatives.
The more diluted solutions showed no toxicity at all. In S1, the low cell viability values can be
explained by the increased osmotic pressure of glycerol which has already been proved on human
cells [39]. The Polysorbate 20, which was found to have an IC50 value of 0.004% (v/v) can easily
distort the cell membrane [25]. On A549 human lung cancer cells and HUVECs even a very minimal
concentration of Polysorbate 20 caused nearly total cell death [40]. Polysorbate is known to increase the
transport of certain drug molecules through cell membranes by a membrane component solubilization
mechanism [41]. It was supposed that this dual effect—the osmotic stress and the distortion of the cell
membrane—was responsible for the dramatically low cell viability of Caco-2 cells. This may well mean
that when a pharmaceutical product has a high osmotic pressure or contains a surfactant with high
HLB value, the cytotoxicity must be reconsidered, because these excipients can enhance the toxicity of
each other in a synergetic way.
In S2, in the presence of ethanol and Capryol PGMC™, the results were controversial. At the
original concentration, BP was the least toxic compound, but at tenfold dilution, it was not statistically
distinguishable from MP, while these two were significantly different from both the control, and the
other esters. The formulated control of the second system had lower cell viability than, the control of
the first system. The parabens alone still showed the same ranking as the S1, it can be assumed, that
the surfactant with low HLB value were responsible for the lower toxicity of BP.
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In the case of the antimicrobial tests, our systems were tested on clinically relevant pathogens
which can represent a variety of possible contaminating agents. However, the exact mechanism of
action of parabens is unknown, and there are various papers describing different pathways. Bredin et al.
found that on E. coli, PP had similar potassium efflux-creating effects as polymyxin. The site of action
was the porin channels, as their specific blockers could protect the bacteria from damage [42]. It was
also reported that they could distort the structure of the cell membrane [43]. It was also a menacing
result, as parabens showed higher affinity to distort phospholipids in mammalian cell membranes than
bacterial ones. A general theory of action, is that like other weak acids used as preservatives (sorbates,
benzoates, propionates, etc.) 4-hydroxybenzoic acid at acidic pH penetrates the cells in a nonionized
way and in the cytosol, it dissolves and the resulting H+ act as the main metabolic disruptive force [44].
According to Thong et al., MP had no direct dependence on the pH, for A. sulphureus and P. viridicatum,
nevertheless, it was able to drastically decrease the production of ochratoxin A for both species [45].
Er et al. reported similar results, where the difference between the inhibition on the growth and the
biofilm formation at pH 6 and pH 7 on Salmonella strains was not significant [46]. A possible way of
resistance to parabens can be the hydrolysis of esters by enzymatic activity [47].
As for the antibacterial results, it can be said that inhibitory potential of parabens differed greatly.
While E. coli, a Gram-negative bacterium showed resistance towards PP and BP, another Gram-negative
strain, P. aureginosa, had nearly total resistance towards all parabens, and only the highest dose of
MP could effectively inhibit it. The S1 formulation was very effective against both species, even the
formulated control, and without any additional paraben could eradicate the microbes. This is greatly
advantageous, as the resistance of P. aeruginosa towards many disinfectants in known [48]. Formulation
S2 which only contained an additional surface-active agent, could not drastically increase the effect
of parabens, and only a small decrease of cell viability could be measured. The formulated control
of S2 had no effect on P. aeruginosa, but was effective against E. coli, as this bacterium was overall
more sensitive to the parabens. The only Gram-positive bacterium, S. aureus, was resistant to MP, EP
and PP and susceptible only to BP. S1 caused total cell death and the presence of Capryol PGMC™
could effectively increase the effect of the shorter esters. It can be stated that Gram-positive and
negative strains have different sensitivity towards surface-active agents and as the results indicate,
the Gram-positive species are more vulnerable to them, supposedly due to their different cell wall
structure. Smaoui et al., found that 1% (w/w) MP had limited effect on S. aureus, which correlates with
our results [49]. The controversial susceptibility to the different parabens means, that for the tested
bacteria, there was no linear relationship between the length of alkyl chain and the antimicrobial effect
as it was stated in literature [50], but rather every ester must be tested against a given microbe in a
solution that has the composition of the final pharmaceutical product.
The cell wall of Candida species is different from its bacterial counterparts, it is not a rigid structure,
but a more flexible outer layer of the cells, capable of structural changes [51]. The cell wall of C. albicans
and C. glabrata are relatively well described. They are similar, the main reported difference being
their adhesin-like proteins, which are mostly important for the pathogenicity and mask them from the
immune system [52]. However, the cell wall of C. parapsilosis is not described precisely, but it also has
similar attributes that of the C. albicans [53]. Despite this, C. parapsilosis was the most resistant of all
the tested yeasts, and the only one where the 50% cell viability threshold was reached, in case of the
highest concentration of PP formulated in the first system. C. parapsilosis was also sensitive to ethanolic
solutions of parabens, but both S1 and S2 had less effect on it as cell viability was always above 20% for
the formulated systems. For C. glabrata and C. albicans, there was a small, but persistent gap between
the formulated and the non-formulated test solutions. At the same time, it could be noted, that in most
scenarios MP was as effective as the longer parabens which correlates well with the broad range study
of Matos et al. [54]. On all fungi, but mostly on C. parapsilosis, a very interesting pattern could be seen:
the control samples, which only consists of the given ester, ethanol and PBS had better inhibition effect
than the formulated systems. Nor a high amount of glycerol—and the osmotic pressure of it—nor the
two surfactant, could enhance the effect of parabens, on the contrary, they increased the survivability
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of the fungi. The exact mechanism is poorly understood and needs further investigation. Also, for the
tested fungi, no linear relationship was found between the length of alkyl chain and the antimicrobial
activity, as stated in previous results [55].
Generally, the S1 totally eradicated all bacteria, so they were less resistant to the dual effect of
osmotic pressure and solubilization, while S2 had limited effects on them. The fungi were mostly
sensitive to the parabens, but both formulations proved to be less effective on them, than the ethanolic
solutions of parabens. The two systems presented similar patterns of cytotoxicity on human cells, but
as it was seen on the bacteria and the fungi, but the length of the paraben alone is not informative to to
predict the cytotoxic and antimicrobial properties.
4. Materials and Methods
4.1. Materials
Methyl 4-hydroxybenzoate and glycerol were purchased from Hungaropharma (Budapest,
Hungary). Ethyl 4-hydroxybenzoate was obtained from Acros Organics (Geel, Belgium), propyl
4-hydroxybenzoate from Alfa Aesar (Karlsruhe, Germany), butyl 4-hydroxybenzoate from TCI
(Zwijndrecht, Belgium). Capryol PGMC™ was a kind gift from Gattefossé (Lyon, France).
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Dulbecco’s Modified Eagle’s
Medium (DMEM), phosphate buffered saline (PBS), Trypsin-EDTA, Heat-inactivated fetal bovine
serum (FBS), L-glutamine, non-essential amino acids solution, gentamycin, RPMI-1640 broth
with L-glutamine and Mueller-Hinton broth were purchased from Sigma-Aldrich (Budapest,
Hungary). Non-essential amino acids solution and penicillin-streptomycin mix were obtained from
VWR (Debrecen, Hungary), L-glutamine and GlutaMax™ supplement was from Thermo Fisher
(Budapest, Hungary).
4.2. Cell Culture
Caco-2 cell line was obtained from the European Collection of Cell Cultures (ECACC, Salisbury,
United Kingdom). Cells were grown in plastic cell culture flasks in Dulbecco’s Modified Eagle’s
Medium, supplemented with 3.7 g/L NaHCO3, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1%
(v/v) non-essential amino acids solution, 1% (v/v) L-glutamine, 100 IU/mL penicillin, and 100 µg/mL
streptomycin at 37 ◦C in an atmosphere of 5% CO2. The cells were routinely maintained by regular
passaging and glutamine was supplemented by GlutaMax™. The cells used for cytotoxic experiments
were between passage numbers 20 and 40.
4.3. Cytotoxicity Tests
The cytotoxic effects of the various solutions were evaluated using the
3-(4,5-dimethylthiazol-2-yl))-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity method. Caco-2
cells in complete medium were seeded on 96-well plate at a final density of 10.000 cells/well.
After 7 days, the medium was removed, and the cells were incubated for 30 min with the test solutions.
All test solutions were prepared 10 min before the start of incubation. The samples were removed,
and a 5 mg/mL MTT solution (MTT salt solved in PBS) was added to each well. The plates were
incubated for 3 h, then the MTT solution was removed and 0.1 mL of a solution of isopropanol—1 M
hydrochloride acid (25:1) was added to dissolve the formed formazan crystals. The absorbance was
measured at 570 nm against a 690 nm reference with a Thermo-Fisher Multiskan Go (Thermo Fisher,
Budapest, Hungary) microplate reader. Cell viability was expressed as a percent of the cell viability of
the untreated control cells, which were incubated with PBS for 30 min.
4.4. Antimicrobial Tests
Antibacterial and antifungal susceptibility testing was performed using standard broth
microdilution method in accordance with the recent EUCAST protocols (E.Dis 5.1, E.Def 7.3.1) against
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Pseudomonas aeruginosa (ATCC® 27853™), Escherichia coli (ATCC® 25922™), Staphylococcus aureus
(ATCC® 43300™), Candida albicans (ATCC® 10231™), C. parapsilosis (ATCC® 22019™) and C. glabrata
(ATCC® 90030™) [56,57]. Briefly, the broth microdilution assays were performed using 96-well
standard microtitre plates, where the given concentrations of the tested compounds are prepared
in RPMI-1640 and Mueller-Hinton medium for fungal species and bacteria, respectively. All test
solutions were prepared 10 min before the start of incubation. The final volume of each well contained
100 µL from the tested compounds and 100 µL fungal or bacterial inoculum. The inoculum size
was 2 × 103 cells/mL and 5 × 105 CFU/mL for Candida species and bacteria species, respectively.
Plates were incubated for 24 h at 37 ◦C. After the incubation period, the absorbance was measured by
a Thermo-Fisher Multiskan Go (Thermo Fisher) microplate reader at 492 nm and 600 nm for fungal
species and bacterial species, respectively. Prominent inhibition was determined based on turbidity as
at least 50% growth reduction compared with the compound-free control. Percent change in turbidity
was calculated on the basis of absorbance (A) as 100% × (Awell − Abackground)/(Acompound-free well −
Abackground). The background was measured from the microbe-free well.
4.5. Statistical Analysis
All data were analysed using GraphPad Prism (version 6; GraphPad Software, Inc., La Jolla, CA,
USA). In case of MTT-assay results, the data was presented as means ± SEM. Each cell viability value
represents the mean of twelve independent, parallel wells, with the highest and lowest absorbance
values were excluded when calculating the mean. After that, at each concentration, the means of
different solutions where compared with one-way ANOVA test followed by Tukey’s test when all
solutions were compared to each other (Table 3).
Table 3. Result of Tukey's multiple comparison test performed on the results of Caco-2 cells. FC:
formulated control, Methyl: formulated methyl-paraben, Ethyl: formulated ethyl-paraben, Propyl:
formulated propyl-paraben, Butyl: formulated butyl-paraben. * p < 0.05; ** p < 0.01; *** p < 0.001,
**** p < 0.0001.
ANOVA Followed by Tukey’s Multiple Comparisons Test Level of Significance
Parabens alone, 0.2% Methyl vs. Ethyl ns
Parabens alone, 0.2% Methyl vs. Propyl **
Parabens alone, 0.2% Methyl vs. Butyl ****
Parabens alone, 0.2% Ethyl vs. Propyl **
Parabens alone, 0.2% Ethyl vs. Butyl ****
Parabens alone, 0.2% Propyl vs. Butyl ns
Parabens alone, 0.02% Methyl vs. Ethyl ns
Parabens alone, 0.02% Methyl vs. Propyl **
Parabens alone, 0.02% Methyl vs. Butyl *
Parabens alone, 0.02% Ethyl vs. Propyl *
Parabens alone, 0.02% Ethyl vs. Butyl ns
Parabens alone, 0.02% Propyl vs. butyl ns
Parabens alone, lower concentrations all are insignificant
S1, 0.2% Formulated control vs. Methyl *
S1, 0.2% FC vs. Ethyl ****
S1, 0.2% FC vs. Propyl ****
S1, 0.2% FC vs. Butyl ****
S1, 0.2% Methyl vs. Ethyl ****
S1, 0.2% Methyl vs. Propyl ****
S1, 0.2% Methyl vs. Butyl ****
S1, 0.2% Ethyl vs. Propyl ns
S1, 0.2% Ethyl vs. Butyl ns
S1, 0.2% Propyl vs. Butyl ns
S1, 0.02% FC vs. Methyl *
S1, 0.02% FC vs. Ethyl ****
S1, 0.02% FC vs. Propyl ****
S1, 0.02% FC vs. Butyl ****
S1, 0.02% Methyl vs. Ethyl ****
S1, 0.02% Methyl vs. Propyl ****
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Table 3. Cont.
ANOVA Followed by Tukey’s Multiple Comparisons Test Level of Significance
S1, 0.02% Methyl vs. Butyl ****
S1, 0.02% Ethyl vs. Propyl ***
S1, 0.02% Ethyl vs. Butyl ***
S1, 0.02% Propyl vs. Butyl ns
S1 lower concentrations all are insignificant
S2, 0.2% Formulated control vs. Methyl ****
S2, 0.2% FC vs. Ethyl ****
S2, 0.2% FC vs. Propyl ****
S2, 0.2% FC vs. Butyl ****
S2, 0.2% Methyl vs. Ethyl ns
S2, 0.2% Methyl vs. Propyl ns
S2, 0.2% Methyl vs. Butyl **
S2, 0.2% Ethyl vs. Propyl ns
S2, 0.2% Ethyl vs. Butyl **
S2, 0.2% Propyl vs. Butyl **
S2, 0.02% FC vs. Methyl *
S2, 0.02% FC vs. Ethyl ns
S2, 0.02% FC vs. Propyl ns
S2, 0.02% FC vs. Butyl **
S2, 0.02% Methyl vs. Ethyl *
S2, 0.02% Methyl vs. Propyl *
S2, 0.02% Methyl vs. Butyl ns
S2, 0.02% Ethyl vs. Propyl ns
S2, 0.02% Ethyl vs. Butyl *
S2, 0.02% Propyl vs. Butyl *
S2 lower concentrations all are insignificant
Previously, all data group were analysed with Shapiro-Wilk test for Gaussian distribution and
Bartlett’s test for equal variances. In each case we used significance level p < 0.05. In case of
antimicrobial tests the results of four parallel, independent wells were represented as means ± SEM.
5. Conclusions
Different test systems containing parabens as preservatives were formulated (S1: glycerol and
polysorbate 20; S2: ethanol and Capryol PGMC™) to observe any kind of correlation between the
cytotoxicity and microbial inhibitory potential of parabens. The cytocompatibility and antimicrobial
activity of parabens depends on the length of alkyl chains, the chemical environment and the targeted
cells. The IC50 values of different parabens can be modified by other excipients. Co-solvents (glycerol,
ethanol) and surfactants (Polysorbate 20 and Capryol PGMC) can modify the cytotoxicity and
antimicrobial activity of different parabens. The mechanism of these connections may be different,
because surfactants may solubilize membrane components and disrupted the membrane integrity,
while co-solvents resulted in the damage of mitochondria in the cells. It can be concluded that in vitro
data are not necessarily predictive, but complemented with in vivo experiments could be informative.
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